THC is one of the cannabinoids involved in the “entourage effect” stated earlier so it is ideal for inclusion in CBD supplementation. A recent article on full-spectrum CBD demonstrates the importance of THC inclusion by stating, “In hemp THC is a minor constituent and appears only in trace amounts under 0.3% by dry weight, as required by the U.S. government for hemp products. THC mimics the action of anandamide, a neurotransmitter naturally produced in the human body, and binds to CB1 receptors in the endocannabinoid system found mostly in the brain. The extremely low levels of THC in hemp make hemp oil non-psychoactive and safe for all ages to use.”
The wide range of benefits contained in full-spectrum CBD extracts means some CBD merchants have either ceased to sell, or scale down the promotion of CBD isolate, in comparison to the whole-plant extract variety. Companies and individuals who extract CBD themselves are realising that cannabis has more to offer medicinally than just CBD or THC, and that there is little to no reason to not include all that this “super-plant” has to offer in the extraction process.
Given the results of this study, it would seem to confirm that full-spectrum extract is preferable over CBD isolate for most CBD users, but CBD isolate is still frequently used and believed by some to be more effective than full-plant extract. This belief is led by the idea that CBD is the only medically sought after cannabinoid in the cannabis plant, aside from THC. Many CBD isolate users are under the impression that by consuming only the CBD cannabinoid and no terpenes or any other “unnecessary” components of the plant, they are getting a more powerful or effective dose of CBD. When vaping a CBD extract, which as stated previously, is considered to be the most efficient and quick-acting method of administering CBD, isolate users may feel that they are taking the most efficient route to CBD consumption. While this method might be efficient, the lack of entourage effect means the benefits are reduced when compared to full-spectrum CBD consumption.
This has left some users concerned not just with which form of extracted CBD is most effective or what the proper dosage for them may be, but also with which method of supplementation gives the user the most relief in the right amount of time. Some of the most common methods include applying it sublingually, topically, or taking it in capsules. Vaping cbd is regarded by many to be the most bio-available way to administer, and as such, this has led to an increase in the demand for CBD isolate. This form of CBD is different from full-spectrum CBD extract in that it only contains CBD and none of the other cannabinoids, terpenes, or healthy fatty acids that commonly result from the whole-plant extraction process.
However, CBD isolate does have something to offer CBD users that full-spectrum extracts does not. The fact that full-spectrum extracts invariably contain low levels of THC means that some users prefer to play it safe and stick to pure CBD by itself, out of fear of failing a drug test or experiencing a form of “high”, although both of these occurrences have been found to be fairly unlikely.
Whole-plant extracts typically contain a carefully measured amount of the cannabis plant’s most prominent cannabinoid, THC, although usually not in a large enough amount to have any psychological effects. In many countries, a certain percentage of THC is illegal, so it is vital to know the amount of this cannabinoid when manufacturing products that contain full-spectrum CBD. When present together, CBD and its cannabinoid colleagues, as well as terpenes, produce what is known as an entourage effect. The synergistic relationship between cannabinoids and terpenes has been shown to increase the healing properties of each.
The public profile of CBD has soared in recent years, with users using it to treat all manner of ailments and conditions. It can be consumed in a variety of ways, ranging from simple oral consumption to topical use and even vaping. There are two main forms of CBD on the market. These are ‘full spectrum’ CBD and CBD isolate. There are a number of key differences between the two, which we will look at in this article. We will also look at methods of consumption, as this can have dramatic impact on the efficacy of CBD. As we will see, full-spectrum CBD is more popular, and for good reason, but isolate has certain benefits that might appeal to different CBD users.
A. The agency has received reports of adverse events in patients using cannabis or cannabis-derived products to treat medical conditions. The FDA reviews such reports and will continue to monitor adverse event reports for any safety signals, with a focus on serious adverse effects. Consumers and healthcare providers can report adverse events associated with cannabis or cannabis-derived products via the FDA’s MedWatch reporting system, either online or by phone at 1-800-FDA-1088. For more information, please see the FDA’s webpage on MedWatch.
A. No. There are no other FDA-approved drug products that contain CBD. We are aware that some firms are marketing CBD products to treat diseases or for other therapeutic uses , and we have issued several warning letters to such firms. Under the FD&C Act, any product intended to have a therapeutic or medical use, and any product (other than a food) that is intended to affect the structure or function of the body of humans or animals, is a drug. Drugs must generally either receive premarket approval by FDA through the New Drug Application (NDA) process or conform to a “monograph” for a particular drug category, as established by FDA’s Over-the-Counter (OTC) Drug Review. CBD was not an ingredient considered under the OTC drug review. An unapproved new drug cannot be distributed or sold in interstate commerce.
5. Why hasn’t FDA approved more products containing cannabis or cannabis-derived compounds for medical uses?
Regarding imports, if it appears that an article is adulterated, misbranded, in violation of section 505 of the FD&C Act, or prohibited from introduction or delivery for introduction into interstate commerce under section 301(ll) of the FD&C Act, such article will be refused admission (see section 801(a)(3) of the FD&C Act [21 U.S.C. § 381(a)(3)]).
With respect to products labeled to contain “hemp” that may also contain THC or CBD, as mentioned above it is a prohibited act under section 301(ll) of the FD&C Act to introduce or deliver for introduction into interstate commerce any animal food to which THC or CBD has been added.